GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Q32 Bio Inc.
The stock of Q32 Bio, a biotech company focused on treating autoimmune diseases, reflects the potential of its lead drug. Its price trajectory is a classic biotech story, with the value determined by expectations of clinical trial results.
Share prices of companies in the market segment - Pharma immune
Q32 Bio is a biopharmaceutical company developing drugs to restore immune balance in the treatment of autoimmune and inflammatory diseases. We have classified it in the Pharma: Immunology category. The chart below shows how investors value companies in this broad field.
Broad Market Index - GURU.Markets
Q32 Bio is a biopharmaceutical company developing treatments to restore immune balance in autoimmune and inflammatory diseases. It is a component of the GURU.Markets index, and the chart below shows how its stock compares to the market, reflecting investor expectations.
Change in the price of a company, segment, and market as a whole per day
QTTB - Daily change in the company's share price Q32 Bio Inc.
Q32 Bio Inc.'s daily share price fluctuations reflect the extreme volatility inherent in biotech companies. This metric measures the company's sensitivity to news about clinical trials of its autoimmune disease drugs.
Daily change in the price of a set of shares in a market segment - Pharma immune
Q32 Bio Inc. is a biotech company. This chart highlights the sector's extreme volatility. Comparison with QTTB, which focuses on immune disease treatments, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Q32 Bio is a biotech company focused on immunology. Its shares, like many in the sector, are highly volatile and react to news about clinical trials. These science-driven movements are part of the complex and diverse landscape of the entire stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Q32 Bio Inc.
Q32 Bio Inc.'s year-over-year performance is a story of drug development for the treatment of autoimmune and inflammatory diseases. Its 12-month market cap is entirely dependent on clinical trial data. The success of its approach, which targets the regulation of the complement system and immune cells, could offer new treatment options.
Annual dynamics of market capitalization of the market segment - Pharma immune
Q32 Bio, a recent IPO, is a biotech company developing drugs to treat autoimmune and inflammatory diseases. Its performance reflects investor confidence in its scientific platform. The chart below shows how its high potential and early-stage risks compare to the sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Shares of Q32 Bio, a company focused on immunology, operate in a world of their own, far removed from economic cycles. Their performance against the market is a pure bet on a scientific breakthrough. Positive clinical trial data can trigger explosive growth, completely ignoring market downturns, and conversely, demonstrating independence from macroeconomics.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Q32 Bio Inc.
Q32 Bio is a clinical-stage biotech company targeting autoimmune and inflammatory diseases. Its monthly performance is entirely dependent on the results of its clinical trials. Data on its leading drugs is a binary outcome for its stock.
Monthly dynamics of market capitalization of the market segment - Pharma immune
This chart reflects the dynamics of the volatile biotech sector. For Q32, a clinical-stage company, it's the backdrop. Its movements show how successes and failures in immunology clinical trials have impacted investor sentiment.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Q32 Bio is a clinical-stage biotech company developing drugs to treat autoimmune and inflammatory diseases. Its value is almost entirely dependent on the results of clinical trials. The broader market has little impact on Q32 Bio shares; their fate is decided in labs and clinics, which can lead to sharp movements counter to the market trend.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Q32 Bio Inc.
Q32 Bio, a biotech company focused on treating autoimmune and inflammatory diseases by restoring immune balance, is extremely volatile. Its weekly stock price is a direct reaction to the publication of preclinical and early clinical trial data for its platform.
Weekly dynamics of market capitalization of the market segment - Pharma immune
Q32 Bio operates in the highly competitive immunology sector, where investor sentiment drives broad trends. Any significant success or failure in the industry impacts everyone's risk appetite. The chart will show whether QTTB is following the general flow of biotech speculation or whether its unique scientific news is creating its own trend.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
As a biotech company, Q32 Bio often ignores broader market trends. Its fate depends not on GDP or inflation, but on the results of clinical trials. The chart below clearly demonstrates how QTTB shares can rise or fall on their own news, while the overall market moves in a different direction.
Market capitalization of the company, segment and market as a whole
QTTB - Market capitalization of the company Q32 Bio Inc.
The Q32 Bio chart is another story of hope in the field of immunology. This biotech's market cap reflects investors' faith in its approach to treating autoimmune and inflammatory diseases. Its performance is a speculative bet that its drugs will successfully complete clinical trials.
QTTB - Share of the company's market capitalization Q32 Bio Inc. within the market segment - Pharma immune
Q32 Bio is a biotech company developing drugs to restore immune balance in autoimmune and inflammatory diseases. Its market share is based on its targeted approach. The chart shows how the market perceives its ability to develop highly effective treatments for this complex group of diseases.
Market capitalization of the market segment - Pharma immune
Q32 Bio is a biotech company developing drugs to restore immune balance in autoimmune and inflammatory diseases. The chart below shows the market capitalization of the entire immunology pharmaceutical sector. This represents the quest to fine-tune the immune system.
Market capitalization of all companies included in a broad market index - GURU.Markets
Q32 Bio is a biopharmaceutical company developing treatments to restore immune balance in autoimmune and inflammatory diseases. Its market capitalization reflects its scientific approach. The chart below shows the economic weight of companies working in this field.
Book value capitalization of the company, segment and market as a whole
QTTB - Book value capitalization of the company Q32 Bio Inc.
Q32 Bio's book value represents scientific capital for the treatment of autoimmune and inflammatory diseases. Its foundation consists of patents on two lead drug candidates and cash allocated to advance them through clinical trials. The chart below shows how the company uses its financial resources to test its scientific hypotheses.
QTTB - Share of the company's book capitalization Q32 Bio Inc. within the market segment - Pharma immune
Q32 Bio, a biopharmaceutical company, is focused on R&D. Its laboratories are its main physical asset. The S_BCap_Seg graph shows its small share of physical infrastructure, which is typical for a company in the research stage.
Market segment balance sheet capitalization - Pharma immune
Q32 Bio is a clinical-stage biotech company focused on treating autoimmune and inflammatory diseases. Its value lies in its scientific potential. A book value chart shows that its assets are almost entirely intangible, typical for an innovative company with little to no production.
Book value of all companies included in the broad market index - GURU.Markets
Q32 Bio Balance is a scientific platform for restoring immune balance. The company's assets include the rights to develop its antibodies and the financial resources for clinical trials. This material base is aimed at creating drugs that don't completely suppress the immune system, but rather precisely regulate it for the treatment of autoimmune diseases.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Q32 Bio Inc.
Q32 Bio is a biopharmaceutical company developing therapies for autoimmune and inflammatory diseases. Its book value is its cash reserves. Its market capitalization is the market's net valuation of the potential of its scientific platforms and the likelihood of its drugs succeeding in future clinical trials.
Market to book capitalization ratio in a market segment - Pharma immune
Q32 Bio is a biotech company developing treatments for autoimmune and inflammatory diseases. Its value lies in its scientific developments. The chart shows how the market values the potential of its drug candidates relative to its book value, which is primarily comprised of cash.
Market to book capitalization ratio for the market as a whole
Q32 Bio is a biopharmaceutical company focused on treating autoimmune and inflammatory diseases. Its value is almost entirely determined by the potential of its research portfolio. The chart clearly demonstrates the gap between market capitalization and book value, which is typical for biotech companies.
Debts of the company, segment and market as a whole
QTTB - Company debts Q32 Bio Inc.
Q32 Bio, a clinical-stage biotech, is using debt to finance the development of its immunomodulatory drugs. This chart shows the capital raised for clinical trials aimed at treating autoimmune and inflammatory diseases by restoring immune balance.
Market segment debts - Pharma immune
Q32 Bio is a clinical-stage biotech company developing drugs for the treatment of autoimmune and inflammatory diseases. Its financial structure is typical for biotech: no sales revenue and a complete reliance on equity capital to fund R&D. This chart shows its cash reserves and their burn rate.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Q32 Bio Inc.
Q32 Bio is a biotech company focused on treating autoimmune and inflammatory diseases. This chart shows whether it uses debt. For a company with early-stage drugs, debt is a high-risk investment but can help accelerate clinical trials and market entry.
Market segment debt to market segment book capitalization - Pharma immune
Q32 Bio is a clinical-stage immunology company. This chart for the biotech sector illustrates how the industry as a whole raises capital to fund lengthy and expensive research. It provides context for assessing the financial viability of a company that does not yet have commercial products or stable revenue.
Debt to book value of all companies in the market
Q32 Bio is a biotech company developing drugs to restore immune balance in autoimmune and inflammatory diseases. This chart, which shows the market's debt-to-book value ratio, is important for assessing the investment climate. The market's willingness to finance long and risky developments determines the future of companies like Q32 Bio.
P/E of the company, segment and market as a whole
P/E - Q32 Bio Inc.
Q32 Bio is a biotech company developing drugs to restore immune balance in autoimmune and inflammatory diseases. This chart reflects its belief in its scientific approach. Its value shows how willing investors are to fund the development of a new class of drugs aimed at "repairing" the immune system rather than suppressing it.
P/E of the market segment - Pharma immune
Q32 Bio Inc. is a biotech company. This chart shows the average P/E ratio for the biotech sector. Comparing the company's P/E to this benchmark allows us to understand how highly the market values its approach to treating autoimmune diseases compared to the average prospects of other biotech developments.
P/E of the market as a whole
Q32 Bio is a biotech company developing drugs to restore immune balance in autoimmune and inflammatory diseases. This is a highly competitive but also promising field. This chart shows the risk appetite in biotech. The company's valuation depends on the success of its clinical programs and investor confidence that its approach will be better or safer than existing treatments.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Q32 Bio Inc.
Q32 Bio is a clinical-stage biotech company developing drugs to restore immune balance in autoimmune and inflammatory diseases. The chart reflects speculative investor expectations, which are entirely dependent on positive clinical trial results and the potential of its therapy.
%20P%2FE%20Q32%20Bio%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Q32-Bio-Inc.&v=1772513602745 "Chart of the company's future (projected) P/E Q32 Bio Inc.")
Future (projected) P/E of the market segment - Pharma immune
Q32 Bio is a clinical-stage biopharmaceutical company developing treatments to restore immune balance in autoimmune and inflammatory diseases. This chart shows its expected future profitability, allowing us to assess how highly the market values its targeted approach to immune regulation.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772513602747 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
Q32 Bio is a clinical-stage biotech company developing drugs to restore immune balance in autoimmune and inflammatory diseases. Its value reflects the expected future success of its drug candidates and is completely unrelated to overall market forecasts.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513602749 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Q32 Bio Inc.
Q32 Bio Inc. is a clinical-stage biopharmaceutical company developing drugs to restore immune balance in autoimmune and inflammatory diseases. Its financial indicators reflect clinical trial expenses. This chart shows the investment in developing a new class of targeted therapy.
Profit of companies in the market segment - Pharma immune
Q32 Bio Inc. is a clinical-stage biopharmaceutical company developing therapies to restore immune balance in autoimmune and inflammatory diseases. This chart shows the profitability of the immunology segment. The company's R&D expenses impact current overall profitability, but its innovative drugs have the potential to become breakthroughs in the treatment of a wide range of complex diseases.
Overall market profit
Q32 Bio is a clinical-stage biotech company developing drugs to restore immune balance in autoimmune and inflammatory diseases. Its valuation is driven by research progress. Against the backdrop of general economic cycles, illustrated by this chart, Q32 Bio is working to develop innovative treatments, solving complex medical problems.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Q32 Bio Inc.
Q32 Bio is a clinical-stage biopharmaceutical company developing drugs to restore immune balance in autoimmune and inflammatory diseases. This chart reflects analysts' expectations for future earnings, based on the potential of its innovative approaches. It demonstrates the market's confidence in the company's ability to successfully complete clinical trials.
%20profit%20of%20the%20company%20Q32%20Bio%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Q32-Bio-Inc.&v=1772513602830 "Graph of future (projected) profit of the company Q32 Bio Inc.")
Future (predicted) profit of companies in the market segment - Pharma immune
Q32 Bio Inc. is a clinical-stage biopharmaceutical company developing therapies to restore immune balance in autoimmune and inflammatory diseases. This chart shows profitability forecasts for the immunology pharmaceutical segment. It reflects expectations for new treatment approaches targeting the underlying causes of the disease.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772513602846 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
Q32 Bio is a biotech company specializing in the treatment of autoimmune and inflammatory diseases. Their success depends on their ability to fund long-term clinical trials. The market's total return forecast reflects investors' risk appetite, which increases during periods of economic optimism, making it easier to raise capital.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513602874 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Q32 Bio Inc.
Q32 Bio Inc. is a biotechnology company developing therapies for the treatment of autoimmune and inflammatory diseases. Currently in the clinical stage, it has no revenue. P/S ratio will be a key indicator after the product's launch to assess its commercial potential.
P/S market segment - Pharma immune
Q32 Bio is a clinical-stage biopharmaceutical company developing treatments for autoimmune and autoinflammatory diseases by restoring immune balance. This chart illustrates the high investor expectations for their innovative approach to immunology and the potential of their drugs to generate future revenue.
P/S of the market as a whole
Q32 Bio is a biotech company developing therapies to restore immune balance in autoimmune and inflammatory diseases. It has no revenue, and its valuation reflects the potential of its developments. This chart, based on actual revenue, clearly demonstrates that Q32 Bio's valuation is a bet on a new approach to treating complex diseases.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Q32 Bio Inc.
Q32 Bio is a biotech company developing therapies to restore immune balance in autoimmune and inflammatory diseases. This chart reflects investor expectations for future revenue from its targeted therapies, which may offer a new approach to treating a wide range of diseases caused by immune system dysfunction.
%20P%2FS%20Q32%20Bio%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Q32-Bio-Inc.&v=1772513602927 "The graph of the company's future (projected) P/S Q32 Bio Inc.")
Future (projected) P/S of the market segment - Pharma immune
Q32 Bio Inc. is a clinical-stage biopharmaceutical company developing treatments for autoimmune and inflammatory diseases by restoring immune balance. This chart shows how the market perceives the future commercial potential of its innovative drugs. It compares it to other immunology companies, reflecting confidence in its scientific approach.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772513602943 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
Q32 Bio is a biotech company developing drugs to restore immune balance in autoimmune and inflammatory diseases. This approach to treatment is nuanced and complex. This chart shows revenue expectations for the entire market, and QTTB demonstrates how a deep scientific understanding of the immune system is opening new horizons for drug development.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513602958 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Q32 Bio Inc.
Q32 Bio Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune and inflammatory diseases. Because its drugs are in development, the company does not yet generate revenue from their sales. Any revenue shown in this chart likely stems from collaboration agreements.
Sales of companies in the market segment - Pharma immune
Q32 Bio is a biotech company developing therapies for autoimmune and inflammatory diseases. At this stage, its revenue, if any, may come from licensing agreements. This chart allows investors to assess the financial support from partners, which is essential for conducting research.
Overall market sales
Q32 Bio is a clinical-stage biopharmaceutical company developing treatments for autoimmune and inflammatory diseases. Its value is determined solely by the progress of its scientific programs. This overall market performance chart is irrelevant to Q32 Bio's valuation, which is driven solely by clinical data.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Q32 Bio Inc.
Q32 Bio is a clinical-stage biopharmaceutical company developing therapies for autoimmune and inflammatory diseases. Its revenue forecast is based entirely on expectations of future research success. This chart shows analysts' speculative assessment of its potential in this competitive field.
%20sales%20of%20the%20company%20Q32%20Bio%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Q32-Bio-Inc.&v=1772513603019 "Schedule of future (projected) sales of the company Q32 Bio Inc.")
Future (projected) sales of companies in the market segment - Pharma immune
Q32 Bio is a clinical-stage biopharmaceutical company developing drugs for the treatment of autoimmune and inflammatory diseases. This chart shows projected revenue for the entire immunology segment. It provides insight into the size and growth prospects of this market, which is important for Q32 Bio's commercial potential.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772513603032 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
Q32 Bio is a clinical-stage biopharmaceutical company developing therapies for autoimmune and inflammatory diseases. Its value is determined by the potential of its scientific developments. This chart of overall market expectations reflects investor risk appetite, which is critical for funding long-term and capital-intensive biotech projects.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513603038 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Q32 Bio Inc.
Q32 Bio is a clinical-stage biopharmaceutical company developing drugs for the treatment of autoimmune and inflammatory diseases. This chart reflects its current research focus. It doesn't show profit, but rather the effectiveness of capital management for clinical trials.
Market segment marginality - Pharma immune
Q32 Bio is a biotechnology company developing treatments for autoimmune and inflammatory diseases by restoring immune balance. This chart reflects the average profitability in the immunology sector. It serves as a benchmark for assessing the commercial potential of Q32 Bio's innovative approaches to treating complex diseases compared to existing therapeutic standards.
Market marginality as a whole
Q32 Bio Inc. is a clinical-stage biopharmaceutical company developing therapies for autoimmune and inflammatory diseases. This gross margin chart shows the current picture, while Q32's true value lies in the future potential of its scientific developments, which could change the lives of millions of patients.
Employees in the company, segment and market as a whole
Number of employees in the company Q32 Bio Inc.
Q32 Bio is a clinical-stage biopharmaceutical company developing therapies for autoimmune and inflammatory diseases. The growth of its scientific and clinical teams, visible in the chart, demonstrates progress in the development of key drugs and the transition to later, larger-scale trials.
Share of the company's employees Q32 Bio Inc. within the market segment - Pharma immune
Q32 Bio Inc. is a clinical-stage biopharmaceutical company developing treatments for autoimmune and inflammatory diseases. This chart highlights its scientific focus on immunology. It shows the percentage of leading immunologists and researchers working on innovative therapies to restore balance to the immune system that Q32 Bio brings together.
Number of employees in the market segment - Pharma immune
Q32 Bio Inc. is a biopharmaceutical company developing drugs to restore immune balance in autoimmune and autoinflammatory diseases. This chart shows employment in the immunology sector. The growing number of specialists in this field indicates progress in understanding the immune system and the development of a new generation of targeted therapies.
Number of employees in the market as a whole
Q32 Bio Inc. is a biopharmaceutical company developing drugs to treat autoimmune and inflammatory diseases. Immunology is one of the fastest-growing fields in medicine. This chart illustrates overall employment, and investments in such companies contribute to the creation of high-tech jobs in science and medicine.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Q32 Bio Inc. (QTTB)
Q32 Bio is a clinical-stage immunology company. Its market value is determined by investor expectations. This chart shows the "hope value" of a single scientist. Investors evaluate not current sales, but the likelihood that a small team will create a blockbuster, which is reflected in the enormous market value per employee.
%20of%20the%20company%20Q32%20Bio%20Inc.%20(QTTB)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Q32-Bio-Inc.-QTTB&v=1772513603158 "Chart of market capitalization per employee (in thousands of dollars) of the company Q32 Bio Inc. (QTTB)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
Q32 Bio is an immunology company developing treatments for autoimmune and inflammatory diseases. Like many biotech companies, its market cap per employee reflects investors' faith in its scientific platform. Its high market cap indicates high expectations for the clinical trial results being conducted by its team.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772513603201 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
Q32 Bio is a clinical-stage biopharmaceutical company developing therapies for autoimmune and inflammatory diseases. Its valuation reflects its hopes for scientific success. This chart reflects how investors assess the potential of a small team of scientists to create drugs that could transform the treatment of serious diseases.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513603252 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Q32 Bio Inc. (QTTB)
Q32 Bio is a clinical-stage biotech company developing treatments for autoimmune and inflammatory diseases. The company has no commercial products. This negative graph shows how much investor capital is burned for each scientist working on this complex area of medicine.
%20Chart%20Q32%20Bio%20Inc.%20(QTTB)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Q32-Bio-Inc.-QTTB&v=1772513603284 "Company Profit Per Employee (in thousands of dollars) Chart Q32 Bio Inc. (QTTB)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
Q32 Bio is a biotech company developing drugs to restore immune balance in autoimmune and inflammatory diseases. This chart reflects the potential value of their scientific approach. It shows the enormous value a small team of scientists can generate if their innovative therapy proves successful and attracts demand in the large immunology market.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772513603315 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
Q32 Bio Inc. is a clinical-stage biopharmaceutical company developing treatments for autoimmune and inflammatory diseases. This chart reflects R&D intensity. It shows the "cost" of the scientific team—the investment per employee required to advance innovative drugs through clinical trials.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513603340 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Q32 Bio Inc. (QTTB)
Q32 Bio is a clinical-stage biopharmaceutical company. This graph, showing zero revenue per employee, is typical for the industry. It illustrates a period when all resources are focused on research and development. Future drug success will lead to explosive growth in this metric.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Q32-Bio-Inc.-QTTB&v=1772513603434 "Sales chart per company employee Q32 Bio Inc. (QTTB)")
Sales per employee in the market segment - Pharma immune
Q32 Bio (QTTB) is a biopharmaceutical company developing treatments for autoimmune and inflammatory diseases by restoring immune balance. This chart shows the average revenue per employee in the pharmaceutical segment. For Q32 Bio, which is in the R&D stage, comparing it to this benchmark (zero) highlights their focus on science rather than current sales.
Sales per employee for the market as a whole
Q32 Bio (QTTB) is a clinical-stage biotech company working in the field of autoimmune diseases. Like other biotechs (RLYB, PASG), there is no revenue from drug sales. This metric is zero and does not reflect efficacy. The company's entire value lies in the potential of its R&D portfolio.
Short shares by company, segment and market as a whole
Shares shorted by company Q32 Bio Inc. (QTTB)
Q32 Bio is a clinical-stage biotech company specializing in the treatment of autoimmune and inflammatory diseases. This chart reflects the high risk inherent in this sector. "Short sellers" here are betting that clinical trials will fail to demonstrate the required balance of efficacy and safety, and the company will fail.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Q32-Bio-Inc.-QTTB&v=1772513603548 "Short Shares Chart for the Company Q32 Bio Inc. (QTTB)")
Shares shorted by market segment - Pharma immune
Q32 Bio (QTTB) is a biotech company developing therapies to restore immune balance in autoimmune diseases. This chart shows pessimism across the entire immunology sector. The rise in short positions across the industry is a risk-off signal. Investors are hesitant about quick success and fear trial failures. For QTTB, this means the market is skeptical of its entire scientific field.
Shares shorted by the overall market
Q32 Bio (QTTB) is a clinical-stage biotech company. Its value reflects its hope for future success. When this overall pessimism indicator rises, investors are less inclined to hope. They are dumping unprofitable companies en masse, requiring refinancing.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Q32 Bio Inc. (QTTB)
Q32 Bio is a biotech company working on treating autoimmune and inflammatory diseases. This is a complex area of medicine. This indicator is the "pulse" of speculation. It shows how market euphoria can overheat shares on early, encouraging data, followed by a long "cooling" during multi-year clinical trials.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Q32-Bio-Inc.-QTTB&v=1772513603618 "RSI 14 indicator chart for the company's stock Q32 Bio Inc. (QTTB)")
RSI 14 Market Segment - Pharma immune
Q32 Bio is a clinical-stage biotech company focused on treating autoimmune and inflammatory diseases. Their approach is targeted therapy, which aims to regulate the immune system. This chart reflects the overall sentiment in the biotech sector, helping to assess how the market views this speculative industry.
RSI 14 for the overall market
Q32 Bio (QTTB) is a biotech R&D company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic poses the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast QTTB (Q32 Bio Inc.)
Q32 Bio is a clinical-stage biotech developing drugs to restore immune balance in autoimmune and inflammatory diseases. This chart shows the speculative average 12-month price target from analysts, which is almost entirely dependent on their assessment of the company's R&D portfolio.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-QTTB-Q32-Bio-Inc.&v=1772513603675 "A chart showing analyst consensus forecasts for the expected stock price. QTTB (Q32 Bio Inc.)")
The difference between the consensus estimate and the actual stock price QTTB (Q32 Bio Inc.)
Q32 Bio is a biotech company developing targeted therapies to restore immune balance in the treatment of autoimmune and inflammatory diseases. This chart shows the upside and downside potential analysts see in the stock. It measures the gap between the price and forecast, reflecting their confidence in the company's R&D portfolio.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-QTTB-Q32-Bio-Inc.&v=1772513603712 "A chart showing the difference between the consensus forecast and the actual stock price. QTTB (Q32 Bio Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
Q32 Bio is a clinical-stage biotech company developing drugs to "reboot" the immune system in autoimmune and inflammatory diseases. This chart shows general expectations for the immunotherapy sector, reflecting experts' confidence in the success of R&D in this complex field.
Analysts' consensus forecast for the overall market share price
Q32 Bio is a biotech company specializing in developing drugs to treat autoimmune and inflammatory diseases by restoring the balance of the immune system. This chart shows the overall market appetite for risk. For Q32, a clinical-stage company, overall market optimism is critical to attracting the capital needed to fund R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Q32 Bio Inc.
Q32 Bio is a clinical-stage biotech company focused on immunology. They develop drugs (antibodies) designed to rebalance the immune system to treat autoimmune diseases. This chart is a pure indicator of their R&D confidence. It doesn't reflect revenue, but rather a speculative estimate of their scientific progress and clinical trial data.
AKIMA Market Segment Index - Pharma immune
Q32 Bio (QTTB) is a biopharmaceutical company developing drugs to treat autoimmune and inflammatory diseases. Their approach is to rebalance the immune system rather than suppress it. The chart shows the segment average index, helping investors assess how this targeted immune strategy compares to the industry average.
The AKIM Index for the overall market
Q32 Bio is a biotech company developing treatments for autoimmune diseases targeting the complement system and IL-7R. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this clinical-stage research story compares to overall economic trends in immunology.
